Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Declines By 37.3%

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 120,800 shares, a decline of 37.3% from the October 31st total of 192,800 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 29,500 shares, the days-to-cover ratio is presently 4.1 days.

Hedge Funds Weigh In On Aytu BioPharma

A number of hedge funds have recently modified their holdings of AYTU. Dimensional Fund Advisors LP boosted its position in shares of Aytu BioPharma by 54.5% in the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after purchasing an additional 8,311 shares during the period. Armistice Capital LLC bought a new position in shares of Aytu BioPharma in the second quarter worth approximately $736,000. Finally, Stonepine Capital Management LLC boosted its position in shares of Aytu BioPharma by 6.0% in the third quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock worth $1,177,000 after purchasing an additional 28,489 shares during the period. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Stock Performance

NASDAQ AYTU traded down $0.01 during trading hours on Friday, hitting $1.61. 18,152 shares of the company’s stock traded hands, compared to its average volume of 22,925. The business’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $2.50. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $9.90 million, a P/E ratio of -1.31 and a beta of -1.40. Aytu BioPharma has a 52 week low of $1.41 and a 52 week high of $3.45.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Thursday, September 26th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.37). The business had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative net margin of 8.28% and a negative return on equity of 21.89%.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.